QuarterHawk — Equity ResearchQuarterHawk — Equity Research

NewAmsterdam Pharma Company N.V. (NAMS)

Healthcare

No action
Fundamental
3
Sentiment
3
Technical
3

Do Nothing: no breakout stop qualifies — a buy-stop at 20.85 above the settled 20.82 cluster high yields only 1.46 R/R (risk 1.82 vs a 2.66 reward) under the 1.5 floor, and no pullback limit qualifies because price 20.14 is below the SMA50 (21.53) with MACD line -0.57 < 0 and below a declining SMA200 (29.16) without a momentum reclaim — a countertrend bid rather than a dip within an uptrend.

Analysis as of 2026-11-15· more than 2 trading days ago

Company overview

NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical firm focused on developing therapies for cardiometabolic diseases. It is advancing Obicetrapib, a CETP inhibitor, in clinical trials for cardiovascular and Alzheimer's diseases. The company is based in Naarden, the Netherlands.

Fundamental

fair
Fundamental3
Mixed fundamentals

The company has a strong balance sheet but remains pre-commercial with a single-asset dependency and binary clinical risks.

Mixed, catalyst-driven profile: zero debt and roughly $643.1M of cash and marketable securities at 30-Sep-2026 (about four-plus years of current operating burn) plus a first-in-class CETP inhibitor approved in the EU in September 2026, against a $204.9M trailing net loss, negative operating cash flow, single-asset dependency and a binary PREVAIL cardiovascular-outcomes readout whose DSMB recommendation is expected in Q1 2027. Sell-side consensus of $53.75 sits far above the $20.14 share price, while the discounted-cash-flow model returns only $3.13-$3.68 per share because it is driven by a pre-commercial milestone revenue base.

Sentiment

fair
Sentiment3
Forming sentiment

Media sentiment has improved, but retail sentiment remains indeterminate and catalysts are partially priced.

Dominant catalyst is the regulator-confirmed European Commission approval of Ubeslo and Evlarco (obicetrapib) recapped in the 2026-11-04 quarterly update (item sentiment +0.5, direction bullish), but the EC decision itself dates to September 2026 and no dated forward driver falls inside the next 30 days, so the catalyst is only partially priced rather than actionable-now. Media delta is a determinate improvement from a near-flat +0.10 baseline to +0.40 in the scoring window on a thin scored sample, retail is indeterminate (Reddit 403), and the Red-Flag Screen is clean with no severe or moderate cap applied.

Technical

fair
Technical3
Short-term rebound

The stock shows short-term momentum repair but remains in a broader downtrend with no qualifying entry.

Mixed chart, score 3. Bullish side: four consecutive higher regular-session lows off the 52-week low (17.90 on 11-09 → 18.90 → 19.30 → 19.31 → 19.48), price back above EMA9 19.90, WMA9 19.78, WMA21 19.97, DEMA14 19.61, TEMA14 19.83 and the 11-13 daily VWAP 20.04, MACD histogram positive and expanding for three sessions (-0.02 → 0.09 → 0.12 → 0.14) with the line recovering from -0.83 to -0.57, RSI up from 38.9 to 47.3 and Williams %R off a -99.1 washout to -48.6. Limiting side: price remains below SMA20 20.19, EMA21 20.29, SMA50 21.53 and SMA200 29.16, the MACD line is still below zero, ADX14 is 16.7 and falling from 25.9 on 11-02 (no directional trend), and the stock is roughly -52% from its 2026-05-11 high of 42.21. That is a short-term rebound inside an intact downtrend rather than a trend-aligned long, so the read is mixed rather than strong.

You’re looking at 2026-11-15 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.